1,940 results on '"Shepherd, Frances A."'
Search Results
102. Immunotherapy and Lung Cancer
103. Evaluating natural planned exposure protocols on rotavirus shedding patterns in gilts and the impact on their suckling pigs
104. Angiotensin-Converting Enzyme and Aldosterone Serum Levels as Prognostic and Predictive Biomarkers for Cediranib in NCIC Clinical Trials Group Study BR.24
105. Correlation of Dosimetric and Clinical Factors With the Development of Esophagitis and Radiation Pneumonitis in Patients With Limited-Stage Small-Cell Lung Carcinoma
106. Chemotherapy in the Elderly: Standard Chemotherapy or Specific Regimens?
107. Mitochondrial Aconitase ACO2 Links Iron Homeostasis with Tumorigenicity in Non–Small Cell Lung Cancer
108. Rotavirus Infection in Swine: Genotypic Diversity, Immune Responses, and Role of Gut Microbiome in Rotavirus Immunity
109. Dacomitinib compared with placebo in pretreated patients with advanced or metastatic non-small-cell lung cancer (NCIC CTG BR.26): a double-blind, randomised, phase 3 trial
110. Resource Utilization and Costs during the Initial Years of Lung Cancer Screening with Computed Tomography in Canada
111. Epidermal Growth Factor Receptor Inhibitors in the Treatment of Non-small Cell Lung Cancer
112. Validation of the Short-Form McGill Pain Questionnaire-2 in Younger and Older People With Cancer Pain
113. Relationship Between EGFR Expression, EGFR Mutation Status, and the Efficacy of Chemotherapy Plus Cetuximab in FLEX Study Patients with Advanced Non–Small-Cell Lung Cancer
114. Validation of a Histology-Independent Prognostic Gene Signature for Early-Stage, Non–Small-Cell Lung Cancer Including Stage IA Patients
115. A Phase II Trial of Saracatinib, an Inhibitor of src Kinases, in Previously-Treated Advanced Non–Small-Cell Lung Cancer: The Princess Margaret Hospital Phase II Consortium
116. Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial
117. Genome-wide interaction study of smoking behavior and non-small cell lung cancer risk in Caucasian population
118. Helicase-like transcription factor expression is associated with a poor prognosis in Non-Small-Cell Lung Cancer (NSCLC)
119. Long-Term Outcome after En Bloc Resection of Non–Small-Cell Lung Cancer Invading the Pulmonary Sulcus and Spine
120. Upfront Next Generation Sequencing in Non-Small Cell Lung Cancer
121. Automating Access to Real-World Evidence
122. Plasma first: Accelerating lung cancer diagnosis through liquid biopsy.
123. Adjuvant Chemotherapy After Pulmonary Resection for Lung Cancer
124. Surrogate endpoints for overall survival in chemotherapy and radiotherapy trials in operable and locally advanced lung cancer: a re-analysis of meta-analyses of individual patients' data
125. Factors Influencing a Specific Pathologic Diagnosis of Non–Small-Cell Lung Carcinoma
126. Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer
127. Molecular heterogeneity of non‐small cell lung carcinoma patient‐derived xenografts closely reflect their primary tumors
128. The Communal Coping Model and Cancer Pain: The Roles of Catastrophizing and Attachment Style
129. Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non-Small-Cell Lung Cancer Previously Treated With Chemotherapy.
130. Treatment patterns and outcomes in early-stage ALK-rearranged non-small cell lung cancer
131. Progression-free survival and overall survival in phase III trials of molecular-targeted agents in advanced non-small-cell lung cancer
132. Respiratory Influenza Virus Infection Causes Dynamic Tuft Cell and Innate Lymphoid Cell Changes in the Small Intestine
133. Prognostic gene-expression signature of carcinoma-associated fibroblasts in non-small cell lung cancer
134. sj-docx-1-tam-10.1177_17588359221112696 – Supplemental material for The economic value of liquid biopsy for genomic profiling in advanced non-small cell lung cancer
135. sj-docx-1-tam-10.1177_17588359221126151 – Supplemental material for Plasma-first: accelerating lung cancer diagnosis and molecular profiling through liquid biopsy
136. sj-docx-1-cix-10.1177_11769351221136056 – Supplemental material for Optimizing Drug Response Study Design in Patient-Derived Tumor Xenografts
137. Prognostic Gene Signatures for Non-Small-Cell Lung Cancer
138. Clinical Outcomes of Extensive Stage Small Cell Lung Carcinoma Patients Treated With Consolidative Thoracic Radiotherapy
139. A Systematic Review and Canadian Consensus Recommendations on the Use of Biomarkers in the Treatment of Non-small Cell Lung Cancer
140. Randomized Phase II Trial of Concurrent Versus Sequential Bortezomib Plus Docetaxel in Advanced Non–Small-Cell Lung Cancer: A California Cancer Consortium Trial
141. Phase I Trial of Radiation With Concurrent and Consolidation Pemetrexed and Cisplatin in Patients With Unresectable Stage IIIA/B Non–Small-Cell Lung Cancer
142. Non-small-cell lung cancer
143. Complementary Medicine Use Amongst Patients with Metastatic Cancer Enrolled in Phase III Clinical Trials
144. Lung Cancer Driven by BRAFG469V Mutation Is Targetable by EGFR Kinase Inhibitors
145. Effects of Ethnicity on Outcomes of Patients With EGFR Mutation–Positive NSCLC Treated With EGFR Tyrosine Kinase Inhibitors and Surgical Resection
146. Integrating comprehensive genomic sequencing of non-small cell lung cancer into a public healthcare system
147. Optimizing Drug Response Study Design in Patient-Derived Tumor Xenografts
148. Health-Related Quality of Life Outcomes in Patients with Resected Epidermal Growth Factor Receptor–Mutated Non–Small Cell Lung Cancer Who Received Adjuvant Osimertinib in the Phase III ADAURA Trial
149. The economic value of liquid biopsy for genomic profiling in advanced non-small cell lung cancer
150. Plasma-first: accelerating lung cancer diagnosis and molecular profiling through liquid biopsy
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.